Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo
Kelly M. Lohr, Alison I. Bernstein, Kristen A. Stout, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 27, pp. 9977-9982
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Ramón Cacabelos
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 3, pp. 551-551
Open Access | Times Cited: 495
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Javier Blesa, Serge Przedborski
Frontiers in Neuroanatomy (2014) Vol. 8
Open Access | Times Cited: 428
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Nicolas Giguère, Samuel Burke Nanni, Louis‐Éric Trudeau
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 348
Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration
Danielle E. Mor, Elpida Tsika, Joseph R. Mazzulli, et al.
Nature Neuroscience (2017) Vol. 20, Iss. 11, pp. 1560-1568
Open Access | Times Cited: 199
Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications
Mallikarjuna Nimgampalle, Harshini Chakravarthy, Sapana Sharma, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101994-101994
Closed Access | Times Cited: 68
Dimethyl itaconate ameliorates cognitive impairment induced by a high-fat diet via the gut-brain axis in mice
Wei Pan, Jinxiu Zhao, Jiacheng Wu, et al.
Microbiome (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 48
Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases
Martin Kampmann
Nature reviews. Neuroscience (2024) Vol. 25, Iss. 5, pp. 351-371
Closed Access | Times Cited: 34
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits
Shababa T. Masoud, Laura M. Vecchio, Yan Bergeron, et al.
Neurobiology of Disease (2014) Vol. 74, pp. 66-75
Open Access | Times Cited: 144
LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease
Maria Nguyen, Dimitri Krainc
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 21, pp. 5576-5581
Open Access | Times Cited: 133
Dopamine depleters in the treatment of hyperkinetic movement disorders
Joseph Jankovic
Expert Opinion on Pharmacotherapy (2016) Vol. 17, Iss. 18, pp. 2461-2470
Closed Access | Times Cited: 130
Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease
Amy R. Dunn, Kristen A. Stout, Minagi Ozawa, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 11
Open Access | Times Cited: 127
Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Kelly M. Lohr, Shababa T. Masoud, Ali Salahpour, et al.
European Journal of Neuroscience (2016) Vol. 45, Iss. 1, pp. 20-33
Open Access | Times Cited: 102
Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
Yvette C. Wong, Kelvin C. Luk, Kerry Purtell, et al.
Movement Disorders (2019) Vol. 34, Iss. 10, pp. 1406-1422
Open Access | Times Cited: 88
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
Francesco Longo, Daniela Mercatelli, Salvatore Novello, et al.
Acta Neuropathologica Communications (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 87
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Kristen A. Stout, Amy R. Dunn, Carlie Hoffman, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 9, pp. 3927-3938
Closed Access | Times Cited: 83
The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration
Danielle E. Mor, Malcolm J. Daniels, Harry Ischiropoulos
Movement Disorders (2019) Vol. 34, Iss. 2, pp. 167-179
Open Access | Times Cited: 77
Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson’s Disease: a Systematic Review
Michele Goulart dos Santos, Lúcia Emanueli Schimith, Corinne André‐Miral, et al.
Neurotoxicity Research (2022) Vol. 40, Iss. 1, pp. 319-345
Closed Access | Times Cited: 48
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders
Rachel M. Wise, Annika Wagener, Urban M. Fietzek, et al.
Neurobiology of Disease (2022) Vol. 175, pp. 105920-105920
Open Access | Times Cited: 47
The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases
Sarah E. Davis, Abagail B. Cirincione, Ana Catya Jiménez-Torres, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15340-15340
Open Access | Times Cited: 24
In vivoreduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
Marta González-Sepúlveda, Joan Compte, Thaïs Cuadros, et al.
Brain (2023) Vol. 146, Iss. 3, pp. 1040-1052
Open Access | Times Cited: 23
Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity
Meghan L. Bucher, Amy R. Dunn, Joshua M. Bradner, et al.
European Journal of Neuroscience (2024) Vol. 59, Iss. 10, pp. 2483-2501
Open Access | Times Cited: 8
Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP
Stefan Schildknecht, Donato A. Di Monte, Regina Pape, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 6, pp. 541-555
Open Access | Times Cited: 78
Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson’s disease
Jenny-Ann Phan, Kathrine Stokholm, Justyna Zarȩba-Pasławska, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 75
Presynaptic effects of levodopa and their possible role in dyskinesia
Eugene V. Mosharov, Anders Borgkvist, David Sulzer
Movement Disorders (2014) Vol. 30, Iss. 1, pp. 45-53
Open Access | Times Cited: 70
Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?
Michael R. Post, Ori J. Lieberman, Eugene V. Mosharov
Frontiers in Neuroscience (2018) Vol. 12
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top